ARTICLE | Deals
Carisma to reach NASDAQ via Sesen merger
After evaluating options, Sesen chooses Carisma option among dozens of bids, creating third incarnation of public company
September 21, 2022 7:36 PM UTC
Via its merger with Sesen, macrophage-based cell therapy company Carisma will become a NASDAQ-traded company as it moves its lead program through Phase I testing.
The deal will create a third incarnation of the publicly traded entity. Sesen Bio Inc. (NASDAQ:SESN) was itself formed via a business combination, wherein Eleven Biotherapeutics Inc. acquired Viventia Inc. in 2016 and subsequently renamed itself...